BioWorld: The Daily Biopharmaceutical News Source
Neomorph Inc. has signed another billion-dollar deal to develop molecular glue degraders, this time with Abbvie Inc. It’s the third agreement in the past year the five-year-old company has signed with big pharma companies in a space with lots of collaborative deals.
BioWorld: The Daily Biopharmaceutical and Medical Technology …
These cookies are used to enable social media sharing or “like” buttons on our services. They also provide the ability to link your account or engage with our content on or through a social media platform such as Facebook, Twitter or LinkedIn.
BioWorld Science - Articles
Jan 3, 2025 · Daily news focused on drug discovery, delivery and preclinical research. Coverage includes: Congress highlights, key studies from peer-reviewed journals, chemical structure images, pharmacology news that delineates drug/receptor and enzyme/target cell interactions, newly reported experimental models, and relationships between genes and diseases to gain insight into underlying biological ...
Year in review 2024: Top deals | BioWorld
Dec 24, 2024 · The top 10 deals announced in 2024. The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...
Duality Biologics reports preclinical findings with B7-H3/PD-L1 ...
Nov 8, 2024 · Duality Biologics Ltd. presented preclinical data on DB-1419, a potentially first-in-class bispecific antibody-drug conjugate (ADC) consisting of a humanized antibody targeting B7-H3 and PD-L1 conjugated to a DNA topoisomerase I inhibitor under development for the treatment of cancer.
BB-203, a potentially best-in-class anti-PD-L1/anti-VEGF VHH …
Nov 22, 2024 · Bright Biologics LLC reported the discovery and preclinical evaluation of BB-203, an anti-PD-L1/anti-VEGF bispecific antibody (Ab) being developed for the treatment of cancer.
BioWorld MedTech - Articles
3 days ago · South Korea’s Ministry of Food and Drug Safety said it released the world’s first guideline on reviewing and approving generative artificial intelligence-based medical devices Jan. 24, to help establish standards on the technology’s applications in the medical field.
Discovery of AZD-4144, a potent, direct and selective NLPR3 ...
Sep 10, 2024 · Astrazeneca plc recently provided details on the discovery of the potent, direct and selective NLPR3 inflammasome inhibitor AZD-4144 for the treatment of inflammatory diseases; the drug is currently in phase I trials for cardiorenal disease (NCT06491550, NCT06122714).
Preclinical characterization of AZD-9592, an EGFR–c-Met
Researchers from Astrazeneca plc presented preclinical data for AZD-9592, the novel epidermal growth factor (EGFR)–c-Met bispecific antibody-drug conjugate (ADC) targeting key oncogenic drivers in non-small-cell lung cancer (NSCLC).
China - Articles - BioWorld
6 days ago · Breaking news and analysis of the global biotechnology, pharmaceutical, medical device and medical technology sectors. In-depth coverage of innovation, business, financing, regulation, science, product development, clinical trials and more